Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPA | P38571 | 1/20 | 0.54 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.40 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | GABRP | O00591 | 1/20 | 0.35 |
| ▸ | GABRD | O14764 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13008729 | 0.95 | LIPA (0.50) | LIPABRD4EPHX1APOBEC3AAPOBEC3G | |
| SCHEMBL24197361 | 0.85 | BRD4 (0.50) | BRD4EPHX1SMN1; SMN2MAPTGAA | |
| SCHEMBL26647720 | 0.85 | BRD4 (0.50) | BRD4EPHX1SMN1; SMN2MAPTGAA | |
| SCHEMBL2036054 | 0.85 | — | — | |
| Ammonia Solution, Strong SCHEMBL27687914 | 0.83 | — | — | |
| SCHEMBL27692577 | 0.83 | LIPA (0.45) | LIPABRD4GAAEPHX2ALDH1A1 | |
| SCHEMBL29228545 | 0.81 | LIPA (0.51) | LIPAEPHX1APOBEC3AAPOBEC3GKDM4E | |
| SCHEMBL28392206 | 0.79 | LIPA (0.61) | LIPAEPHX1APOBEC3AAPOBEC3GKDM4E | |
| SCHEMBL13520091 | 0.78 | BRD4 (0.42) | BRD4MAPTGAAEPHX2ALDH1A1 | |
| SCHEMBL9264525 | 0.78 | LIPA (0.59) | LIPAEPHX1APOBEC3AAPOBEC3GKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260130872-A1 | Substituted Bicyclic Compounds, Compositions and Methods of Use | DEEP APPLE THERAPEUTICS, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| US-11932601-B2 | Immunoregulatory agents | FLEXUS BIOSCIENCES, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| US-20220274926-A1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES INC (US) | 2022-09-01 | — | — | US | disclosed |
| US-11242319-B2 | Immunoregulatory agents | FLEXUS BIOSCIENCES, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| US-20190092729-A1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES, INC. | 2019-03-28 | — | — | US | disclosed |
| EP-3215141-A2 | IMMUNOREGULATORY AGENTS | Flexus Biosciences, Inc. (US) | 2017-09-13 | — | — | EP | disclosed |
| WO-2016073738-A2 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES, INC. (US) | 2016-05-12 | — | — | WO | disclosed |
| US-6329373-B1 | AMIDES WITH HYDROXYAMIDES AS ENZYME INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS, LTD. (GB) | 2001-12-11 | — | — | US | disclosed |
| EP-0873304-B1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARM (GB) | 2001-09-05 | — | — | EP | disclosed |
| US-6127427-A | ACTIVE HYDROXAMIC ACIDS INVOLVED IN TISSUE DEGRADTION AND ALSO ARE INHIBITORS OF THE RELEASE OF TUMOUR NECROSIS FACTOR FROM CELLS; RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, OSTEOPENIAS SUCH AS OSTEOPOROSIS, PERIODONTITIS, VISION DEFECTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2000-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11242319-B2 | Immunoregulatory agents | IDO1, IDO2, INMT | LIPA 2642/4885BRD4 1694/4885EPHX1 325/4885 |
| US-20260130872-A1 | Substituted Bicyclic Compounds, Compositions and Methods of Use | GIPR, GLP1R, SIGMAR1 | LIPA 1073/4885BRD4 2060/4885EPHX1 4248/4885 |
| US-20190092729-A1 | IMMUNOREGULATORY AGENTS | IDO1, IDO2, INMT | LIPA 2642/4885BRD4 1694/4885EPHX1 325/4885 |
| US-11932601-B2 | Immunoregulatory agents | IDO1, IDO2, INMT | LIPA 2642/4885BRD4 1694/4885EPHX1 325/4885 |
| US-20220274926-A1 | IMMUNOREGULATORY AGENTS | IDO1, IDO2, INMT | LIPA 2642/4885BRD4 1694/4885EPHX1 325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.